<DOC>
	<DOCNO>NCT02182336</DOCNO>
	<brief_summary>The objective trial quantify effect oral single-dose ( 480 mg ) steady-state BI 201335 NA ( 240 mg BID ) intestinal hepatic cytochrome P450 ( CYP ) P-glycoprotein ( P-gp ) probe drug mean predict drug interaction . The AUCs probe drug caffeine , warfarin , omeprazole , dextromethorphan , midazolam , digoxin assess .</brief_summary>
	<brief_title>Effects BI 201335 NA Cytochrome P450 P-glycoprotein Activity Using Probe Drug Cocktail Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation Healthy male female subject age ≥18 ≤55 year accord follow criterion : Complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead EKG ( electrocardiogram ) ( include determination QTcB , QtcF interval ) , clinical laboratory test ; acceptable finding Weighing least 50 kg , BMI ≥18.5 BMI ≤29.9 kg/m2 ( Body Mass Index ) Volunteers must leave research unit , day overnight stay , include period even Day1 morning Day 5 , even Day 9 morning Day 24 Volunteers must willing complete studyrelated activity Any find medical examination ( include blood pressure , pulse rate EKG ) deviate normal clinical relevance , assess investigator Active diseases gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , musculoskeletal , immunologic , rheumatologic , hormonal , neurological system , cancer , bleed disorder require current medical treatment , may unstable , may exacerbate participation study Any evidence clinically relevant concomitant disease , define exclusion criterion 2 , include limited relevant chronic acute infection Surgery gastrointestinal tract ( except appendectomy endoscopic removal colon polyp ) History presence allergy study drug ( e.g. , BI 201335 NA , caffeine , warfarin , vitamin K , omeprazole , dextromethorphan , digoxin , midazolam , omeprazole ) component drug class , history drug allergy , opinion physician responsible , contraindicate participation Concomitant drug , nutraceuticals , herbal remedy opinion investigator ( consultation BI medical monitor pharmacokineticist ) , would interfere either absorption , distribution metabolism BI 201335 NA , study drug Use drug , might reasonably influence result trial prolong QT/QTc interval within 30 day prior screen trial completion Use investigational drug within 30 day prior enrollment ; plan usage investigational drug course current study Smoking ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability abstain alcohol day screen 7 day last study drug administration . Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial Any laboratory value outside reference range clinical relevance screening , accord judgment investigator , consultation clinical monitor Known elevate liver enzyme past compound ( experimental market ) Concomitant administration food product know alter P450 enzyme Pgp activity grapefruit juice , Seville oranges , St. John 's Wort Concomitant administration drug could affect bleed ( e.g. , aspirin , clopidogrel , ticlopidine , warfarin addition study warfarin dose , heparin , lowmolecular weight heparin ) Concomitant administration oral contraceptive ( may include 7day washout period ) Inadequate venous access Renal hepatic insufficiency A mark baseline prolongation QT/QTc interval e.g. , repeat demonstration QTcF , QTcB interval &gt; 450 m ) Infection hepatitis B ( HBV ) , hepatitis C virus ( HCV ) , define either hepatitis B surface antigen /or hepatitis B core antibody positive , hepatitis C antibody positive ) Positive Enzymelinked immunosorbent assay ( ELISA ) Human Immunodeficiency Virus ( HIV ) 1 HIV2 Fasting screen laboratory test direct bilirubin within normal range elevate total bilirubin , define 30 % upper limit normal For female subject : Pregnancy plan become pregnant within 2 month study completion Positive pregnancy test screen visit No adequate contraception , e.g. , sterilisation , IUD ( intrauterine device ) , use barrier method contraception least 3 month prior participation study Are willing unable use reliable method barrier contraception ( diaphragm spermicidal cream/jelly condoms spermicidal foam ) , 2 month completion/termination trial Lactation period active breastfeeding time screen 30 day end trial visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>